Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 377 results for stroke

  1. Stroke rehabilitation in adults (NG236)

    This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.

  2. Stroke in adults (QS2)

    This quality standard covers diagnosing and managing stroke in adults (over 16). It includes diagnosis, initial management, acute-phase care, rehabilitation and long-term support for people with stroke. It describes high-quality care in priority areas for improvement.

  3. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

  4. Stroke and transient ischaemic attack

    All NICE products on stroke and transient ischaemic attack. Includes any guidance, advice and quality standards.

  5. Stroke and ischaemic attack: 90% of time on a stroke unit (IND35)

    This indicator covers the proportion of patients who have had an acute stroke who spend 90% or more of their stay on a stroke unit. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG52

  6. Stroke and ischaemic attack: 4-hour admission to a stroke unit (IND34)

    This indicator covers the proportion of people who have had or are having a stroke who are admitted to an acute stroke unit within 4 hours of arrival to hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG51

  7. Alteplase for treating acute ischaemic stroke (TA264)

    Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.

  8. Tenecteplase for treating acute ischaemic stroke (TA990)

    Evidence-based recommendations on tenecteplase (Metalyse) for treating acute ischaemic stroke in adults.

  9. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

    Awaiting development [GID-TA10426] Expected publication date: TBC

  10. Stroke and ischaemic attack: thrombolysis (IND33)

    This indicator covers the proportion of people who have had an acute stroke who receive thrombolysis for stroke. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG50

  11. Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)

    This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.

  12. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  13. Stroke and ischaemic attack: early supported discharge (IND32)

    This indicator covers the proportion of people who had a stroke that are supported by a skilled stroke early supported discharge team. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG49

  14. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  15. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.